Carrier screening for fragile X syndrome, cystic fibrosis, and spinal muscular atrophy often requires distinct molecular diagnostic methods and analysis platforms for each gene.
This poster from Asuragen demonstrates the feasibility of trio carrier screening of FMR1, SMN1/2, and CFTR using existing workflows and a single analysis platform with harmonized electrophoresis conditions across two CE instrument models. This approach reduces hands-on and instrument time and simplifies required instrumentation and consumables, providing a cost-effective option for laboratories who are interested in trio carrier screening.
Offered Free by: Asuragen
See All Resources from: Asuragen
This download should complete shortly. If the resource doesn't automatically download, please, click here.